CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 224 enrolled
Drug / intervention
FS VH S/D 500 s-apr +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02891070
NCT02891070Phase 3Completed

A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated FS VH S/D 500 S-apr (Tisseel) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery.

Baxter Healthcare Corporation·interventional·Posted Sep 7, 2016·Updated Sep 10, 2019

In Brief

A Phase 3 clinical trial evaluating FS VH S/D 500 s-apr and DuraSeal Dural Sealant for Cerebrospinal Fluid Leak. Completed, enrolled 224 participants across 25 sites in 4 countries.

Detailed Summary

The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, Germany, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 7, 2016
Enrollment StartOct 11, 2016
Primary CompletionAug 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.8 years ago

Interventions

FS VH S/D 500 s-aprdrug

DuraSeal Dural Sealantdevice